PhD Position in Functional and Structural Genomics for the Junior Research Group "Brain Tumor Translational Targets"
Deutsches Krebsforschungszentrum (DKFZ)
The DKFZ is committed to increase the proportion of women in all areas and positions in which women are underrepresented. Qualified female applicants are therefore particularly encouraged to apply.
Among candidates of equal aptitude and qualifications, a person with disabilities will be given preference.
To apply for a position please use our online application portal (www.dkfz.de).
We ask for your understanding that we cannot return application documents that are sent to us by post (Deutsches Krebsforschungszentrum, Personalabteilung, Im Neuenheimer Feld 280, 69120 Heidelberg) and that we do not accept applications submitted via email. We apologize for any inconvenience this may cause.
The German Cancer Research Center is the largest biomedical research institution in Germany. With more than 3,000 employees,
we operate an extensive scientific program in the field of cancer research.
The Junior Research Group "Brain Tumor Translational Targets" is offering a
PhD Position in Functional and Structural Genomics
The goal of the project is to develop a novel strategy for glioblastoma (GBM) therapy by harnessing the unique ability of an exosome nanosystem to overcome the blood brain barrier (BBB) and deliver malformin C, a small-molecule inhibitor which specifically targets and leads to death of glioblastoma stem-like cells (GSCs).
GBM, the most common and aggressive primary brain tumor type in adults, is highly resistant to treatment, and has a median survival of ~15 months. This grim prognosis is largely due to two key factors: The BBB, a formidable barrier to brain delivery of drugs, including small molecules; and a sub-population of GBM stem-like cells, GSCs, which are emerging as being responsible for resistance to chemotherapy and radiotherapy. These non-specific treatments, together with a lack of known tumor-specific targets for GSCs, prevents selective eradication of malignant cells, and moreover, leads to severe adverse effects on healthy tissue. Thus, it is of utmost importance to discover new compounds that can reach the tumor and target GSCs to serve as next-generation cancer drugs.
In that respect, we will develop an innovative theranostic exosome drug-nanosystem which crosses the BBB, homes in to the tumor, and delivers malformin C. Malformin C delivered by the exosomes will specifically target GSCs and inhibit tumor growth, whilst sparing healthy cells. Real-time CT tracking of the exosomes with the gold particles will provide unprecedented data regarding biodistribution (BD), pharmacokinetics (PK) and treatment efficacy, and will also enable prediction of response to treatment at an early timepoint based on image-guided analysis of tumor accumulation.
The project requires a master's degree in biology or in a related field with practical experience in a research laboratory. Previous work in cell culture and molecular biology techniques, as well as willingness to work with mouse models are essential. Experience in chemistry and stem cell culture is preferable. Excellent verbal and written communication skills (English) and the ability to work both independently and in a team environment are required.
Interesting, versatile workplace
International, attractive working environment
Campus with modern state-of-the-art infrastructure
Access to international research networks
Doctoral student payment including social benefits
Flexible working hours
Comprehensive training and mentoring program through the Helmholtz International Graduate School
The position is limited to 3 years.
The DKFZ is subject to the regulations of the Infection Protection Act (IfSG). As a consequence, only persons who present proof of immunity against measles as well as against COVID-19 may work at the DKFZ.
For further information please contact
Dr. Violaine Rosenstiel-Goidts, phone +49(0)6221/42-4635.